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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a progressive, debilitating disease associated with
significant clinical burden and is estimated to affect 15 million individuals in the US. Although a large number of
individuals are diagnosed with COPD, many individuals still remain undiagnosed due to the slow progression of the
disorder and lack of recognition of early symptoms. Not only is there under-diagnosis but there is also evidence of
sub-optimal evidence-based treatment of those who have COPD. Despite the development of international COPD
guidelines, many primary care physicians who care for the majority of patients with COPD are not translating this
evidence into effective clinical practice.
Method/Design: This paper describes the design and rationale for a randomized, cluster design trial (RCT) aimed at
translating the COPD evidence-based guidelines into clinical care in primary care practices. During Phase 1, a needs
assessment evaluated barriers and facilitators to implementation of COPD guidelines into clinical practice through
focus groups of primary care patients and providers. Using formative evaluation and feedback from focus groups,
three tools were developed. These include a computerized patient activation tool (an interactive iPad with wireless
data transfer to the spirometer); a web-based COPD guideline tool to be used by primary care providers as a
decision support tool; and a COPD patient education toolkit to be used by the practice team. During phase II, an
RCT will be performed with one year of intervention within 30 primary care practices. The effectiveness of the
materials developed in Phase I are being tested in Phase II regarding physician performance of COPD guideline
implementation and the improvement in the clinically relevant outcomes (appropriate diagnosis and management
of COPD) compared to usual care. We will also examine the use of a patient activation tool - ‘MyLungAge’ -t o
prompt patients at risk for or who have COPD to request spirometry confirmation and to request support for
smoking cessation if a smoker.
Discussion: Using a multi-modal intervention of patient activation and a technology-supported health care
provider team, we are testing the effectiveness of this intervention in activating patients and improving physician
performance around COPD guideline implementation.
Trial registration: ClinicalTrials.gov, NCT01237561
Keywords: COPD, Guidelines, Randomized Clinical Trial, Primary care
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Chronic Obstructive Pulmonary Disease (COPD) is a
serious public health problem and is estimated to affect
15 million individuals in the United States [1]. Although
the prevalence of COPD is increasing, the true burden
of the condition is underestimated because COPD runs
an insidious course and often results in an undiagnosed
initial phase [2]. Consequently COPD is usually not rec-
ognized until it is “clinically apparent and moderately
advanced” [3] and, in fact, COPD is most often diag-
nosed in the fifth or sixth decade even though the dis-
ease may actually start much earlier in life [4,5].
A joint activity between the National Heart, Lung and
Blood Institute and the World Health Organization
helped to develop and publish the Global Strategy for
the Diagnosis, Management, and Prevention of Chronic
Obstructive Lung Disease (GOLD) aimed at increasing
awareness of COPD among health care providers and
the general public and to provide comprehensive treat-
ment guidelines with the goal of decreasing COPD related
morbidity and mortality [6,7]. Despite the development of
GOLD guidelines which provide guidance for appropriate
prevention and management strategies, substantial gaps
exist between the development of the guidelines and their
implementation and dissemination in clinical practice.
Consequently, COPD, which is a systemic disease with
symptoms that overlap with other respiratory illnesses, re-
mains underdiagnosed and undertreated [8-10].
The GOLD COPD guidelines have been developed to
emphasize the importance of performing spirometry to
make a firm diagnosis of COPD as well as to help stage
COPD severity and guide specific treatment steps [11].
The guidelines recommend performing spirometry on all
individuals with a history of repeated exposure to envir-
onmental pollutants and/or cigarette smoke exposure, a
family history of COPD, or the presence of a chronic
cough, sputum production, or shortness of breath. It has
been suggested that “spirometry can be incorporated
into family medicine practice with acceptable levels of
technical adequacy and accurate interpretations” [12]
based on the fact that improvements in spirometry
equipment provide immediate feedback related to tech-
nical adequacy. We were interested in examining whether
spirometry testing could be incorporated into primary
care practice and potentially impact both the diagnosis
and subsequent management of COPD. For the proposed
study, we have provided office spirometers with adequate
technical training to both intervention and usual care
practices.
Current data suggest that there is underutilization of
spirometry for detection and diagnosis of COPD [13].
Various reasons given by primary care physicians for not
utilizing spirometry include: limited access to spirom-
etry, uncertainty about the impact of the test, inadequate
or lack of reproducibility of patient effort, lack of pro-
vider training, difficulty in interpreting results, reim-
bursement issues, and time constraints in busy practice
settings [13,14]. Despite dissemination of the newer re-
commendations in an effort to increase primary care
physician’s utilization of COPD guidelines, many prima-
ry care physicians remain unaware of COPD guidelines
and the diagnosis of COPD continues to be based on
clinical findings alone [15]. In summary, it appears that
many patients with COPD are not diagnosed or staged
with spirometry and therefore undertreated. Given this
treatment gap, primary care providers will be the focus
of the enhanced COPD guideline implementation and
will allow us to examine whether a multi-modal inter-
vention tailored to primary care practices will improve
the care of patients with COPD.
Methods/Design
This 5 year, National Institutes of Health (NIH) funded
study is evaluating the translation of the Gold COPD
guidelines into primary care practice. This study is based
upon the premise that an informed, activated patient will
interact with a prepared, proactive team to improve
COPD diagnosis and management [16-20]. During Phase
I, a needs assessment evaluated barriers and facilita-
tors to implementation of COPD guidelines into clinical
practice through focus groups of primary care patients
and providers. Using formative evaluation and feedback
from the focus groups, three tools were developed, re-
fined and pilot tested. These include: 1) a patient activa-
tion tool on an iPad platform, 2) a Lung Age decision
support tool to be used by primary care providers, and
3) a COPD patient education toolkit. During Phase I,
procedure manuals, study protocols, and data collection
instruments were also developed and pilot tested. Dur-
ing Phase II, a block, randomized design cluster trial
(RCT) is currently underway with 30 primary care prac-
tices throughout the state of Rhode Island and south-
eastern Massachusetts. The effectiveness of the materials
developed in Phase I is being tested in Phase II regarding
physician performance of COPD guideline implemen-
tation and the improvement in the clinically relevant
outcomes (appropriate diagnosis and management of
COPD) compared to usual care. We are also examining
the use of the patient activation tool (iPad) - ‘MyLungAge’
to prompt patients to talk with their health care provider
regarding their lung health and risk for COPD (Figure 1).
For the RCT of primary care practices, the unit of
randomization is the practice. Practice, provider, and pa-
tient level outcomes are being assessed that include: pre-
and post-assessment of practice characteristics, provider
characteristics, and patient information based on chart
audits. Patient chart audits are based on two samples: 1)
one is based on an identified sample of at-risk or COPD
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2) the other is based on a de-identified random audit of
charts from all practices. The first audit based on an
identified sample of at-risk or COPD patients, who gave
Informed Consent, are being conducted in the pre- and
post-intervention periods. A random chart audit of
de-identified patient outcomes both pre- and post-
intervention is being conducted to determine the degree
of selection bias inherent in the informed consent pro-
cess. In addition, semi-quantitative assessments of the
reach of the intervention are being undertaken on a
regular basis through counting the number of ‘hits’ on
the MyLungAge (iPad) patient activation tool located in
each of the intervention practices and the number of
tests initiated on the spirometer for each of the interven-
tion providers. To better understand the workflow is-
sues, strengths and weaknesses of our implementation
strategy, a qualitative study of physicians’ understanding
and adherence to the COPD guidelines, and a qualitative
study of patients’ attitudes and perceptions regarding ac-
ceptance of COPD management recommendations and
COPD medication adherence are being undertaken one
year post intervention. This study is approved by the
Memorial Hospital of RI Institutional Review Board.
Providers
We are performing a two-group RCT, testing the effec-
tiveness of translating the COPD guidelines into clinical
practice, with primary care physicians’ practices as the
unit of randomization and evaluation. The intervention
arm receives an intervention of academic detailing, an
iPad-based patient activation tool that will be placed in
the examination rooms, a netbook running a COPD
guideline decision support tool, a COPD patient educa-
tion toolkit including a website, and a portable spirom-
eter and a printer. The usual care arm receives visits on
the same schedule as the academic detailing visits, a
website link to the GOLD Guidelines, a printer, and a
portable spirometer. The intervention is of one-year du-
ration. We are evaluating the use of the interactive tool
and use of the patient activation tool through tracking
software.
Patients
A cover letter was sent to a random selection of eligible
patients (patients 40 years or older who had been seen
at least once in the past 2 years (active patients) by their
primary care provider). The patients received informa-
tion regarding the study, were informed that their pro-
vider was participating in the study, and that they would
receive a telephone call by one of the research study staff
to invite them to participate in the study, to ask them
to grant permission for auditing of their medical rec-
ord at baseline and one-year post intervention, and to
obtain Informed Consent. During the telephone call,
patients received additional information regarding the
study, were asked to provide audio consent and com-
pleted a 15-minute telephone interview that included
demographic and medical history data and informa-
tion regarding the patient’s knowledge, skills and be-
haviors necessary to create an activated patient for
managing their own health care (PAM-a patient acti-
vation measure) [21].
Measures
Data collection for practices includes: type of practice
(HMO, single specialty, etc.); degree of managed care;
service options (dietitian, nurse counseling, etc.,); num-
bers of personnel (physicians, RN, LPN, Nurse Practi-
tioners, medical assistants, physician assistants, clerical,
other); use of non-physician personnel, use of ancil-
lary services in office (office laboratory, phlebotomy,
dietitian, consultants); ancillary services in the building;
who returns phone calls (physician vs. other); record
Intervention Arm
Receive Portable Spirometer
Spirometry training of medical staff 
Provide clinician with web-based COPD guideline tool
Provide clinician with patient activation tool
Provide clinician with COPD patient education toolkit
Train clinicians (tools, integration into workflow)
Academic Detailing Visits (2)
Baseline and Post-Intervention Chart Audits
Exit Interviews
Usual Care Arm
Receive Portable Spirometer
Spriometry training of medical staff 
Nonacademic detailing visits (2)
Baseline and Post-Intervention Chart Audits
Exit Interviews
Recruitment of 30 Primary Care Practices
Randomization of physician practices
15 practices per arm, 1 primary care provider per practice, data collection, follow-up
Figure 1 Overview of the RCT study design in phase II of translating the COPD guidelines into primary care practice.
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onment (rural, urban, suburban), socioeconomic class of
patients seen; office organization (evening hours, weekend
hours); and volume of visits (number scheduled, number
of unscheduled, total number of patients, number of pa-
tient care hours, number no shows). Data collection of
providers includes: 1) demographic information (age, gen-
der), years in practice, type of provider (physician, nurse
practitioner, physician assistant), specialty (general practi-
tioner, family physician, obstetrics/gynecology, medicine/
pediatrics, general internist, other); 2) practice characteris-
tics (number of office visits, nursing home visits, and
home visits seen in a typical week); 3) self-report of pre-
ventive screening (cholesterol screening, glucose screening
for diabetes, self-report of counseling for smoking cessa-
tion, diet, physical activity) and 4) self-reported familiarity
with COPD guidelines and feelings about COPD guide-
lines. Patient information from medical records includes:
1) socio-demographic factors- age, gender, race/ethnicity,
insurance status, pharmacy benefits, marital status, num-
ber of visits in past year; 2) COPD risk factors (tobacco
smoke, occupational dusts and chemicals, smoke from
home cooking and heating fuel); 3) co-morbid conditions
(i.e., coronary heart disease, congestive heart failure, ar-
rhythmias, hypertension, stroke, liver disease, renal dis-
ease, arthritis, diabetes, malignancies, Parkinson’s disease,
depression, osteoporosis); 4) functional status; 5) cachexia;
6) medications; 7) vital signs-height, weight, waist circum-
ference, body mass index; 8) laboratory- hemoglobin,
hematocrit; 9) provider documentation of weight loss,
dietary assessment, dietary treatment or referral, physical
activity assessment, and treatment for smoking cessation
advice/ counseling/referral; 10) indicators needed to per-
form spirometry: dyspnea (worse with exercise, persistent,
increased effort to breathe), chronic cough, chronic spu-
tum 11) provider documentation of the need for pharma-
cotherapy; 12) provider documentation of adverse effects
of COPD medications; and 13) intervention specific
outcomes- documentation of MyLungAge in the chart,
using printed SOAP notes or patient education page
notes, use of the study smoking cessation material, and
documentation of referral to the MyLungAge website. Data
collection by chart audit is performed at baseline and
again one-year post intervention. In addition, charts are
audited for family history of COPD, smoking status, chest
x-rays, ECGs, α1-antitrypsin deficiency screening, COPD
symptoms (prolonged or progressive cough, sputum pro-
duction, persistent or progressive dyspnea), exposure to
lung irritants, exposure to secondhand smoke, documen-
tation of spiromety, documentation of pulmonary disease,
COPD, cystic fibrosis, interstitial lung disease, sarcoidosis,
tuberculosis, pulmonary hypertension, thoracic surgery,
immunizations and vaccines. Adherence to the COPD
guidelines is based on an adherence tool developed by a
consensus panel of 6 individuals with expertise in COPD
and will include information on documentation of: ex-
posure to tobacco smoke and occupational dust and
chemicals; smoking status; appropriate treatment, increase
in symptoms, influenza and pneumococcal vaccine; need
for oxygen therapy; and assessment of history of CVD or
CVD risk factors.
Sample size considerations
The primary aim of this RCT is to determine and com-
pare the proportion of participants who are appropri-
ately diagnosed with COPD between the intervention
and usual care arm. The clusters (i.e. practices) are ran-
domly assigned to the intervention or usual care arm.
Taking the intra-cluster correlation into account in the
planning phase of the study is critical since failure to do
so may result in an underpowered study. The intra-
cluster correlation (r) is estimated to be between 0.01-
0.02 based on previous findings [22]. For this study, we
enrolled 30 practices, 15 for each group. Using a two-
side type I error of 5%, the projected number of random
charts per practice needed for a power of 80% is 35 for
r=0.01 and 52 for r=0.02. Similarly, we assume the esti-
mated percentage of patients who were diagnosed with
COPD varied from 6% for the control group and 12%
for the intervention group. The selection of 100 charts
per practice in the random retrospective chart audits
gives us reasonable power for all projected COPD out-
comes. A total of 3000 charts for the study provide
greater power for multivariate analyses, detecting inter-
action effects, robustness to violations of model assump-
tions. Given that we have audited 3,604 baseline charts,
we have increased efficiency to detect weaker relation-
ships between variables.
Statistical analyses
Initially, descriptive statistics such as frequency tables
for each categorical variable, and minimum, maximum,
range, median, mean and standard deviation for each
continuous variable will be used to summarize the data
as well as detect outliers, data entry mistakes, and miss-
ing values. Classical longitudinal plots will be used to
identify trends over time in both practice and individual
levels. Chi-squared tests, t-tests or non-parametric tests
will be used to assess the effectiveness of the randomi-
zation procedures by comparing intervention and con-
trol groups on baseline variables. Data analyses will be
performed using SAS 9.1.3 (SAS Institute, Inc, Cary,
North Carolina).
Following intention-to-treat principles, all participants
who have been randomized to the two conditions will be
included in the analyses. We hypothesize that a greater
proportion of patients in the intervention arm will
be appropriately diagnosed with COPD after one year
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generalized linear models using GEE (generalized es-
timating equations) approach and generalized linear
mixed models to evaluate the independent effect of
intervention after adjusting for patient and provider level
covariates, important demographic and confounding fac-
tors. To compare COPD guideline adherence to the
treatment algorithm recommended for primary care
physicians after a one-year intervention in the usual
care arm compared to the intervention arm, we will
examine the dichotomous variable of whether or not
a provider will adhere to the COPD treatment algorithm
after a one-year intervention.
Outcomes
Outcomes are being measured by medical record audit
of 125 randomly selected patients per practice at base-
line and one year post intervention; a random chart
audit of de-identified patient outcomes both pre- and
post-intervention to determine the degree of selection
bias inherent in the informed consent process; and a
chart audit of those patients who gave informed consent
on the iPad patient activation tool in the intervention
practices. A total of 180 charts are being audited per
practice.
Time plan
The development of the program began in July, 2009
and the study will be completed in June, 2014. Provider
recruitment started in October, 2010 and was com-
pleted in March, 2012 and patient recruitment began
in December, 2010 and was completed in June, 2012.
Discussion
In order to effectively overcome COPD guideline imple-
mentation problems, we need to better understand why
primary care providers are underdiagnosing and under-
treating patients with COPD and the barriers and facili-
tators to more fully implement the COPD guidelines.
This study has allowed us to incorporate the insights
discovered through qualitative methods in Phase I into
the development of the provider interactive decision
support tool on the netbook combined with the aca-
demic detailing materials. In addition to better under-
standing provider barriers and facilitators to guideline
implementation, understanding patient knowledge, atti-
tudes and behavioral intentions regarding COPD diag-
nosis and management is crucial. This information has
helped us in developing appropriate patient activation
tools, patient education and self-management tools, and
the patient/provider shared decision-making screen in-
corporated into the MyLungAge iPad tool. We are in the
process of utilizing these tools developed in Phase I, in
the cluster design clinical trial in Phase II to determine
the effectiveness of these tools in improving COPD
guideline implementation. The results of this RCT will
provide us with valuable insight into how to enhance im-
plementation of COPD guidelines in primary care
practices.
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